RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:I agree 109%….
So Just curious what we consider near term horizon when it has basically been stated that the panc will not start until sometime in 2025 and the mbc fda meeting is only for guidance to set up a phase 3 so we know that that too will not start until hopeful early 2025 so almost a year from niow.
MInd you if you listen to Canada fan....his quote....The most significant & SP moving milestone will be the FDA type C meeting report.
That, will set the table for phase 3.
Nothing will move the price of the stock until a partnership or BO is in place.
Also there will not be a reverse split IMO as there is too much potential upcoming and a lot of possibilites. Also I still believe that they are in a blackout period, either that or they do not care about the proper reporting to sedi and are willing to pay fines to let shareholders think they are in a blackout. So which is it and do we trust management enough that they are on the up and up to do things right by the book and keep shareholders apprised accordingly. I guess we shall know soon enough if a deal is done near term and I do not mean sometime in 2025, After the fda meeting and BP should have all the info they need as the 2 year os for mbc was done end of May according to the company and should have first patient in for panc folfirinox by months end so really nothing else to wait for. If it's Roche I still cannot fathom that they would be waiting for the fda mbc as they are all tied up in the goblet trials but then again we should know before summer ends imo as there is no other reason to wait unless it is our managment that is holding out IMO of course